Abstract
Purpose
To determine if concomitant administration of docetaxel plus zosuquidar.3HC1 can prolong progression-free survival in patients with metastatic breast cancer.
Methods
A randomized, double-blind, multicenter, placebo-controlled clinical trial comparing docetaxel plus 500 mg zosuquidar.3HCl (DZ) with docetaxel plus placebo (DP).
Results
A total of 170 patients were enrolled and randomly assigned to treatment. The median age was 53 years (range, 31–74 years). 81.7% of patients had prior chemotherapy in the adjuvant setting and 18.3% in the neoadjuvant setting. The median progression-free survival time was statistically different between groups [7.2 months (DZ) vs. 8.3 months (DP)]. Once the stratification factor relative to progression following prior chemotherapy was considered, no significant treatment difference existed.
Conclusion
The combination of zosuquidar.3HCl plus docetaxel is safe. The analysis of efficacy data is complex, but it can be concluded that there is no difference in progression-free survival, overall survival, or response rate in the study as a whole.
Similar content being viewed by others
References
Jemal A, Tiwari RC, Murray T et al (2005) Cancer Statistics 2005. CA Cancer J Clin 55(1):10–30
Levi F, Lucchini F, Negri E et al (2004) Trends in cancer mortality in the European Union and accession countries, 1980–2000. Ann Oncol 15:1425–1431
Early Breast Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 344:1267–1272
Harris J, Morrow M, Norton L (1997) Malignant tumours of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology 1997, 5th edn. Lippincott-Raven, Philadelphia, pp 1557–1616
Mouridsen HT (1992) Systemic therapy of advanced breast cancer. Drugs 44(Suppl 4):17–28
Henderson IC (1991) Principles in the management of metastatic disease, chemotherapy for metastatic disease. In: Harris JR, Hellam S, Henderson IC et al (eds) Breast diseases. Lippincott, Philadelphia, pp 604–665
Gelmon K (1994) The taxoids: paclitaxel and docetaxel. Lancet 344:1267–1272
Ravlin PM, Burris HA, Cook G et al (1995) Phase II trial of docetaxel: advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879–2885
Valero V, Holmes FA, Walters RS et al (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886–2894
Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917–931
Dantzig AH, Shepherd RL, Cao J et al (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171–4179
Gerrard G, Payne E, Baker RJ et al (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukaemia treated with zosuquidar trichloride, daunorubicin and cytarabine. Haematologica 89(7):782–790
Morschhauser F, Zinzani PL, Burgess M et al (2007) Phase I/II trial of a P-glycoprotein inhibitor, zosuqiodar.3HCl trichloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 48(4):708–715
Acknowledgments
We would like to acknowledge Mrs Elaine Sebastian (data manager) and Dr. Z Chapunduka (Medical Director, Lilly) for their assistance with this article.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruff, P., Vorobiof, D.A., Jordaan, J.P. et al. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 64, 763–768 (2009). https://doi.org/10.1007/s00280-009-0925-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-0925-9